DOCSLIB.ORG

Chlorpromazine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

MICONAZOLE CLOTRIMAZOLE ASTEMIZOLE Kappa opioid receptorHSP90 Mu opioidMORPHINE receptor HYDROCHLORIDELanosterol 14-alpha demethylase NeurokininMelanocortin 1 receptor receptor 4 ASIMADOLINE Delta opioid receptor14-alpha sterol demethylase Cyp51A BREMELANOTIDEKETOBEMIDONEBUPRENORPHINE FLUCONAZOLE COSYNTROPIN 14-alphaPOSACONAZOLE sterol demethylase Melanocortin receptorOpioid 5 receptor Cytochrome P450P-glycoprotein 2C8 3 Cytochrome P450 51 Melanocortin receptorTryptophan 3 REPAGLINIDE2-3-dioxygenase GENTIAN VIOLET METHADONECofilin-1 HYDROCHLORIDE Beta amyloid A4 proteinATP-dependent molecularIMATINIB chaperone MK-0893MESYLATE HSP82 ITRACONAZOLE Metabotropic glutamate receptor 6 CytochromeCytochrome P450 121 P450 17A1 Solute carrierPutative family cytochrome22 memberNeurokinin P450 1 130 2 receptor ZIPRASIDONE HYDROCHLORIDELORATADINEIntermediateNALTREXONE conductanceCytohesin-2 calcium-activated potassium channel protein 4 TOLTERODINE SAQUINAVIR Voltage-gatedSarcoplasmic/endoplasmic potassium channel subunitreticulum Kv4.3LINAGLIPTIN calciumNociceptin ATPase 2receptor BIFONAZOLE TRIMIPRAMINE TARIQUIDAR BUDIPINE ATP-binding cassette sub-family G member 2 Dopamine receptorGlycine D2 and receptor D3 HERG PIMOZIDEPregnaneBOSENTAN X receptor MuscarinicMuscarinic acetylcholine acetylcholine receptor M3 receptor M1 LOPERAMIDE FENTANYLHYDROCHLORIDEDRONEDARONEP-glycoproteinLONAFARNIB 1 GLYCOPYRROLATE BROMIDE Monoamine oxidase CholecystokininTALNETANTDROXIDOPA B receptor LEVOBUPIVACAINEFOSTAMATINIB HYDROCHLORIDEIndoleamineDANTROLENE 2-3-dioxygenase KETOCONAZOLE DARIFENACIN IVERMECTINHistamine H4 receptorTransient receptor Epoxidepotential hydrolase cation channel 1 subfamily M member 2 TIOTROPIUM BROMIDE Dopamine D5 receptor LOBELINEDNA damage-inducible transcriptCytochrome TROGLITAZONE3 protein P450 24A1 Voltage-dependent L-type calcium channel subunit alpha-1C AMIFOSTINE ISOFLUROPHATECytochromeSerotonin P450 (5-HT) 2D6 receptor COPPER Muscarinic acetylcholine receptor M4 Dopamine D1 receptorADMGABA-A receptor; agonistAMODIAQUINE GABA site Cytochrome P450 21 SCOPOLAMINE AcetylcholinesteraseDONEPEZIL HYDROCHLORIDEVoltage-gatedSphingomyelin T-type phosphodiesterase calcium channelThromboxane-A alpha-1G subunit synthase ECOPIPAM BUPIVACAINE HYDROCHLORIDEDOXORUBICIN NISOLDIPINE Muscarinic acetylcholine receptors; M1 & M2 GANAXOLONEONDANSETRON CytochromeCytochrome P450Indoleamine P450 11A1 2A2ILOPROST 2-3-dioxygenase 2 Muscarinic acetylcholineDOMPERIDONE receptor M2 APOMORPHINE HYDROCHLORIDESerotonin 3 receptorMultidrugAdenosine (5HT3) resistance A2a receptor associated protein CARIPRAZINEROTIGOTINE HYDROCHLORIDECLEBOPRIDEBRADANICLINEFLUSPIRILENE Human immunodeficiency virus type 1 integraseALBENDAZOLE ALPRAZOLAMBASIMGLURANTPENFLURIDOLAnti-estrogen binding site (AEBS) Neuronal acetylcholineESREBOXETINE receptor protein alpha-7Sodium subunit channelTyrosine-protein protein type II alpha subunit kinase FYN Muscarinic acetylcholine receptor M5 Dopamine D4 receptorSerotonin 3a (5-HT3a) receptor FENDILINEPENTOBARBITALQUINAPRILAdenosine A3Voltage-gated receptor L-type calcium channel alpha-1C subunit ATROPINE Dopamine D3 receptorCHLORDIAZEPOXIDESALMETEROLBeta-3GABA-A adrenergic receptor; receptor anion channelVoltage-gated N-type calciumCILNIDIPINE channel alpha-1B subunit CARIPRAZINE Acetylcholine receptor protein delta chainGABA receptor beta-3LACIDIPINE subunit FLUPENTIXOLGABA-ATransporterDopamine receptor;Matrix receptor alpha-1/beta-2/gamma-2 metalloproteinase-2CytochromeVoltage-gated P450 2J2L-type calcium channel alpha-1D subunit TIPROLISANT Histamine H2 receptor TRETOQUINOL Adrenergic receptor alpha Histamine H1 receptorROPINIROLE SerotoninP2X 4 (5-HT4) Toll-likepurinoceptor receptor receptor 4 Voltage-gated 7 L-type calciumEstrogen-relatedMOXISYLYTE Arachidonatechannel alpha-1S receptor subunit 15-lipoxygenase gammaNIFEDIPINE Cerebral cortex alpha adrenergic receptorUDP-glucuronosyltransferaseANASTROZOLE 1A4 TOLAZAMIDE Adenosine A1 receptor DESLORATADINE AURANOFINAldehyde oxidase OXYBUTYNIN BOPINDOLOL NILVADIPINE PICLOZOTAN IMIQUIMODBeta-1 adrenergicACLARUBICIN receptor Voltage-gated L-typeCaspase-3 calciumETOPOSIDE channel Dopamine D2 receptorTROPISETRON DANAZOL PIZOTYLINE VERAPAMILMultidrug resistance-associated protein 7 ZOTEPINE BERBERINE CHLORIDE CLENBUTEROL MARAVIROC CLOZAPINE VOLINANSERIN CABERGOLINEPROPRANOLOL HYDROCHLORIDE BLONANSERINSerotonin 2b (5-HT2b)PROPOFOL receptor CENICRIVIROCC-C chemokineDIETHYLSTILBESTROL MESYLATE receptor type 5 PAROXETINE NALUZOTANCholecystokininCANDESARTANAdrenergic receptor receptor beta OLANZAPINE BIFEPRUNOX Voltage-gated potassium channel subunit Kv1.5 EPERISONE FLUOXETINE HYDROCHLORIDE Serotonin 2a (5-HT2a)Serotonin receptor 1a (5-HT1a) receptorMultidrugBeta-2 adrenergic and toxin receptorextrusion protein 1 Serotonin 5a (5-HT5a) receptor TERFENADINEGlucagon receptor TERCONAZOLE TETRACAINE PALONOSETRONSqualene HYDROCHLORIDE monooxygenaseMultidrugPleiotropic and ABCtoxin effluxextrusion transporter proteinUracil of2 multiplenucleotide/cysteinyl drugs leukotriene receptor Sigma opioid receptor TERBINAFINEGlutamate CILANSETRONNMDA receptor GLUCAGON Serotonin 3 (5-HT3) receptorMETHYLPHENIDATE HYDROCHLORIDECysteinyl leukotrieneCysteinyl leukotriene receptor 2 receptor 1 AMOXAPINE LOXAPINE DEXMETHYLPHENIDATEBUPROPION HYDROCHLORIDEAdenylate cyclasePRANLUKAST CLOTHIAPINECERLAPIRDINEIDALOPIRDINE MITOTANE SodiumROCILETINIBDACOMITINIB channel protein type V alpha subunit Serotonin 7 (5-HT7) receptor PENTAMIDINE FROVATRIPTAN ERLOTINIBMODAFINIL HYDROCHLORIDECysteinyl leukotriene receptor Serotonin 2c (5-HT2c) METHYSERGIDEreceptor ZUCLOPENTHIXOLDopamineMETHYLPHENIDATE transporter CLEMASTINE MuscarinicSerotonin acetylcholine receptor6 (5-HT6) receptor GlutamateNorepinephrine NMDA Epidermalreceptor;SERTRALINE GRIN1/GRIN2BBACITRACIN transporter HYDROCHLORIDE growth factor receptor erbB1 MOSAPRIDE ALFACALCIDOL ZAFIRLUKAST Alpha-1d adrenergic receptor LISURIDE CalmodulinTrypanothione reductase Alpha-2b adrenergic receptorIFENPRODIL PAROXETINEAMBROXOL HYDROCHLORIDECIFENLINE SELEGILINE MAZINDOL BROMOCRIPTINE Sodium channel alpha subunit SerotoninSEMUSTINE 1b (5-HT1b)Serotonin receptor 2 Serotonin(5-HT2) receptor transporter MIRTAZAPINEUDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide)Nischarin pyrophosphoryl-undecaprenol N-acetylglucosamine transferase ARIPIPRAZOLE Solute carrier familyVILAZODONE 22 member 3 Alpha-2a adrenergic receptor Histamine H3 receptor RILMENIDINE CLONIDINE FLUOXETINE FIPAMEZOLENAFTOPIDIL Adrenergic receptor alpha-1VANCOMYCIN Alpha-1b adrenergicAlpha-2c receptor adrenergic receptor DEXMEDETOMIDINE RISPERIDONE CARVEDILOL SERTINDOLEAdrenergic receptor alpha-2 Alpha-1a adrenergic receptor Quinolone resistance protein norA EBASTINE Serotonin 1 (5-HT1)THIORIDAZINE receptor CHLORPROMAZINE.
Recommended publications
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T

    WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
  • Early Protective Effects of Tiotropium Bromide in Patients with Airways Hyperres P O N S I V E N E S S

    Early Protective Effects of Tiotropium Bromide in Patients with Airways Hyperres P O N S I V E N E S S

    European Review for Medical and Pharmacological Sciences 2004; 8: 259-264 Early protective effects of tiotropium bromide in patients with airways hyperres p o n s i v e n e s s C. TERZANO, A. PETROIANNI, A. RICCI, L. D’ANTONI, L. ALLEGRA* Department of Cardiovascular and Respiratory Sciences, Respiratory Diseases Unit, Fondazione E. Lorillard Spencer Cenci, “La Sapienza” University - Rome (Italy) *Institute of Respiratory Diseases, University of Milan, Ospedale Maggiore IRCCS – Milan (Italy) Abstract. – Tiotropium is an anticholiner- Introduction gic drug for Ch ronic Obstructive Pulmonary Di sease (COPD) patients, with a peak b ron- Ti o t rop ium is a qu atern a ry amm o niu m chodilator effect observed after 1.5 to 2 hours and a long duration of action. The aim of our co ngener of atropine. It has been developed study was to quantify the early protection of a as a lon g-acting an ticho linergic bro n c h o d i l a- single dose of inhaled tiotropium against metha- tor for inhalation by patients with chronic ob- choline-induced bronchoconstriction in asthmat- s t ructive pu lmon ary d isease (COPD). Dru g ic patients with airway hyperresponsiveness. p ro p e rties o f ant icho lin ergic agent s have Ten subjects (7M, 3F), with history of asthma been well-kno wn to man y cultures for many and a baseline FEV (Forced Expiratory Volume 1 1 1 c e n t u r i e s . In the 1920s the d iscovery o f the sec) >80% of pred icted, were enrolled in the s t u d y.
  • Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse

    Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse

    University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 2012 Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse Pradeep Kumar Vuppala University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Vuppala, Pradeep Kumar, "Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse" (2012). Electronic Theses and Dissertations. 731. https://egrove.olemiss.edu/etd/731 This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. METABOLISM AND PHARMACOKINETICS IN THE DEVELOPMENT OF NEW THERAPEUTICS FOR COCAINE AND OPIOID ABUSE A Dissertation presented in partial fulfillment of requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences in the Department of Pharmaceutics The University of Mississippi by PRADEEP KUMAR VUPPALA April 2012 Copyright © 2012 by Pradeep Kumar Vuppala All rights reserved ABSTRACT Cocaine and opioid abuse are a major public health concern and the cause of significant morbidity and mortality worldwide. The development of effective medication for cocaine and opioid abuse is necessary to reduce the impact of this issue upon the individual and society. The pharmacologic treatment for drug abuse has been based on one of the following strategies: agonist substitution, antagonist treatment, or symptomatic treatment. This dissertation is focused on the role of metabolism and pharmacokinetics in the development of new pharmacotherapies, CM304 (sigma-1 receptor antagonist), mitragynine and 7-hydroxymitragynine (µ-opioid receptor agonists), for the treatment of drug abuse.
  • Non-Steroidal Drug-Induced Glaucoma MR Razeghinejad Et Al 972

    Non-Steroidal Drug-Induced Glaucoma MR Razeghinejad Et Al 972

    Eye (2011) 25, 971–980 & 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11 www.nature.com/eye 1,2 1 1 Non-steroidal drug- MR Razeghinejad , MJ Pro and LJ Katz REVIEW induced glaucoma Abstract vision. The majority of drugs listed as contraindicated in glaucoma are concerned with Numerous systemically used drugs are CAG. These medications may incite an attack in involved in drug-induced glaucoma. Most those individuals with narrow iridocorneal reported cases of non-steroidal drug-induced angle.3 At least one-third of acute closed-angle glaucoma are closed-angle glaucoma (CAG). glaucoma (ACAG) cases are related to an Indeed, many routinely used drugs that have over-the-counter or prescription drug.1 Prevalence sympathomimetic or parasympatholytic of narrow angles in whites from the Framingham properties can cause pupillary block CAG in study was 3.8%. Narrow angles are more individuals with narrow iridocorneal angle. The resulting acute glaucoma occurs much common in the Asian population. A study of a more commonly unilaterally and only rarely Vietnamese population estimated a prevalence 4 bilaterally. CAG secondary to sulfa drugs is a of occludable angles at 8.5%. The reported bilateral non-pupillary block type and is due prevalence of elevated IOP months to years to forward movement of iris–lens diaphragm, after controlling ACAG with laser iridotomy 5,6 which occurs in individuals with narrow or ranges from 24 to 72%. Additionally, a open iridocorneal angle. A few agents, significant decrease in retinal nerve fiber layer including antineoplastics, may induce thickness and an increase in the cup/disc ratio open-angle glaucoma.
  • R Graphics Output

    R Graphics Output

    Dexamethasone sodium phosphate ( 0.339 ) Melengestrol acetate ( 0.282 ) 17beta−Trenbolone ( 0.252 ) 17alpha−Estradiol ( 0.24 ) 17alpha−Hydroxyprogesterone ( 0.238 ) Triamcinolone ( 0.233 ) Zearalenone ( 0.216 ) CP−634384 ( 0.21 ) 17alpha−Ethinylestradiol ( 0.203 ) Raloxifene hydrochloride ( 0.203 ) Volinanserin ( 0.2 ) Tiratricol ( 0.197 ) trans−Retinoic acid ( 0.192 ) Chlorpromazine hydrochloride ( 0.191 ) PharmaGSID_47315 ( 0.185 ) Apigenin ( 0.183 ) Diethylstilbestrol ( 0.178 ) 4−Dodecylphenol ( 0.161 ) 2,2',6,6'−Tetrachlorobisphenol A ( 0.156 ) o,p'−DDD ( 0.155 ) Progesterone ( 0.152 ) 4−Hydroxytamoxifen ( 0.151 ) SSR150106 ( 0.149 ) Equilin ( 0.3 ) 3,5,3'−Triiodothyronine ( 0.256 ) 17−Methyltestosterone ( 0.242 ) 17beta−Estradiol ( 0.24 ) 5alpha−Dihydrotestosterone ( 0.235 ) Mifepristone ( 0.218 ) Norethindrone ( 0.214 ) Spironolactone ( 0.204 ) Farglitazar ( 0.203 ) Testosterone propionate ( 0.202 ) meso−Hexestrol ( 0.199 ) Mestranol ( 0.196 ) Estriol ( 0.191 ) 2,2',4,4'−Tetrahydroxybenzophenone ( 0.185 ) 3,3,5,5−Tetraiodothyroacetic acid ( 0.183 ) Norgestrel ( 0.181 ) Cyproterone acetate ( 0.164 ) GSK232420A ( 0.161 ) N−Dodecanoyl−N−methylglycine ( 0.155 ) Pentachloroanisole ( 0.154 ) HPTE ( 0.151 ) Biochanin A ( 0.15 ) Dehydroepiandrosterone ( 0.149 ) PharmaCode_333941 ( 0.148 ) Prednisone ( 0.146 ) Nordihydroguaiaretic acid ( 0.145 ) p,p'−DDD ( 0.144 ) Diphenhydramine hydrochloride ( 0.142 ) Forskolin ( 0.141 ) Perfluorooctanoic acid ( 0.14 ) Oleyl sarcosine ( 0.139 ) Cyclohexylphenylketone ( 0.138 ) Pirinixic acid ( 0.137 )
  • A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation

    A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation

    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2007-12-28 A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation Frederick Albert Schroeder University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Amino Acids, Peptides, and Proteins Commons, Cells Commons, Enzymes and Coenzymes Commons, Genetic Phenomena Commons, Mental Disorders Commons, Nervous System Commons, and the Therapeutics Commons Repository Citation Schroeder FA. (2007). A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs: a Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/7bk0-a687. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/370 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. A Dissertation Presented by Frederick Albert Schroeder Submitted to the Faculty of the University of Massachusetts Graduate School of Biomedical Sciences Worcester, Massachusetts, USA in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY December 28, 2007 Program in Neuroscience A Role for Histone Modification in the Mechanism of Action of Antidepressant and Stimulant Drugs A Dissertation Presented By Frederick Albert Schroeder Approved as to style and content by: _____________________________________ Alonzo Ross, Ph.D., Chair of Committee _____________________________________ Pradeep Bhide, Ph.D., Member of Committee _____________________________________ Craig L.
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al

    (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al

    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • IJBCP International Journal of Basic & Clinical Pharmacology Antiepileptic

    IJBCP International Journal of Basic & Clinical Pharmacology Antiepileptic

    Print ISSN: 2319-2003 | Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20161495 Review Article Antiepileptic drugs: newer targets and new drugs Vihang S. Chawan, Abhishek M. Phatak*, Kalpesh V. Gawand, Sagar V. Badwane, Sagar S. Panchal Department of Pharmacology, TNMC and BYL Nair Ch. Hospital Mumbai, Maharashtra, India ABSTRACT Received: 10 March 2016 Epilepsy is a common neurological disorder affecting 0.5-1% of the population Accepted: 15 April 2016 in India. Majority of patients respond to currently available antiepileptic drugs (AEDs), but a small percentage of patients have shown poor and inadequate *Correspondence to: response to AEDs in addition to various side effects and drug interactions while Dr. Abhishek Madan Phatak, on therapy. Thus there is a need to develop more effective AEDs in drug Email: abhishekphatak9288 resistant epilepsy which have a better safety profile with minimal adverse @gmail.com effects. The United States food and drug administration (USFDA) has approved eslicarbazepine acetate, ezogabine, perampanel and brivaracetam which have Copyright: © the author(s), shown a promising future as better AEDs and drugs like ganaxolone, intranasal publisher and licensee Medip diazepam, ICA- 105665, valnoctamide, VX-765, naluzotan are in the pipeline. Academy. This is an open- access article distributed under Keywords: Epilepsy, Newer antiepileptic drugs, Eslicarbazepine Acetate, the terms of the Creative Ezogabine (Retigabine), Perampanel, Brivaracetam, Naluzotan Commons Attribution Non- Commercial License, which permits unrestricted non- commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. INTRODUCTION to AEDs or those patient who have suffered from recurrent seizures, may require surgery.
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information

    COPD Agents Review – October 2020 Page 2 | Proprietary Information

    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T

    WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
  • Novel Cyclodextrin Derivatives Presented at the 3Rd European Conference on Cyclodextrins

    Novel Cyclodextrin Derivatives Presented at the 3Rd European Conference on Cyclodextrins

    VOLUME 27. No. 11. NOVEMBER 2013 ISSN 0951-256X October 2-4, 2013, Antalya, Turkey Novel cyclodextrin derivatives presented at the 3rd European Conference on Cyclodextrins This year’s European Conference on Cyclodextrins organized by Prof. Erem Bilensoy, Hacettepe University, Ankara brought 50 oral presentations and 65 posters. Most of the presented works covered the main theme of the congress: ”multifunctional excipient potential of cyclodextrins in pharmaceutical, cosmetic and biomedical industries”. The large number of the presented works dealing with novel cyclodextrin derivatives clearly shows that recently there has been a renewed interest in functionalization of cyclodextrins in order to extend the utilization of these derivatives as tools in catalysis, drug delivery, formulation and stabilization of active molecules and cosmetic ingredients. This short paper gives a brief review of the presented novel cyclodextrin derivatives, summarizes their synthetic methodologies and the field of their applications. Extended abstracts will be published in the Journal of Inclusion Phenomena and Macrocyclic Chemistry after peer review. The references given here are the papers of the cited authors on similar topics presented at the conference. NOVEL CYCLODEXTRIN POLYMERS AND NANOSPONGES Phosphorus-containing cyclodextrin polymers presented by Prof. Catherine Amiel A very attractive new cyclodextrin (CD) based polymeric system presented by Prof. Amiel combines the advantages of cyclodextrin polymers (formation of inclusion complexes with apolar guests) and phosphorus-containing polymers (biocompatibility, calcium affinity). These VOLUME 27. No 11. polymeric systems are promising candidates to be used in biomedical applications that jointly require calcium delivery and transport of lipophilic bioactive molecules. A non-toxic cyclic sodium trimetaphosphate (STMP) was used as a cross-linking agent under basic conditions.